WASHINGTON—The U.S. Food and Drug Administration (FDA) is close to ruling whether to approve for human consumption Aqua Bounty Technologies Inc.’s genetically engineered salmon, AquAdvantage, which has been bioengineered to grow twice as fast as traditional Atlantic salmon.
FDA will hold a three day meeting Sept.19-20, 2010, to consider issues regarding the safety and effectiveness of the new animal drug that is the subject of a new animal drug application (NADA) concerning AquAdvantage salmon produced by AquaBounty Technologies Inc. These genetically engineered Atlantic salmon are intended to grow faster than conventionally bred Atlantic salmon.
FDA also will hold a separate public hearing on the labeling of food, including naming of the food, from the AquAdvantage salmon on Sept. 21, 2010. This public hearing will allow the public to comment on the application of food-labeling principles to food from the AquAdvantage salmon, if the NADA is approved.
Click here for more information.
